Kyverna Therapeutics, Inc. (KYTX): R&D Expense
$133.72M
Year ended 2025-12-31
$115.33M
Trailing 12 months to 2026-06-30
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $133.72M | +18.9% | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | $112.47M | +125.3% | 2026-03-26, From 2024-01-01 |
| 2023-12-31 | $49.92M | n/a | 2025-03-27, From 2023-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | 2025-12-31 | $133.72M | +18.9% |
| Alector, Inc. (ALEC) | 2025-12-31 | $123.06M | -33.8% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $72.72M | -10.9% |
| LENZ Therapeutics, Inc. (LENZ) | 2025-12-31 | $18.67M | -37.4% |
| Invivyd, Inc. (IVVD) | 2025-12-31 | $38.31M | -72.1% |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | $107.83M | -20.1% |
| Lexeo Therapeutics, Inc. (LXEO) | 2025-12-31 | $63.80M | -13.9% |
| Tectonic Therapeutic, Inc. (TECX) | 2025-12-31 | $63.49M | +53.5% |
| Replimune Group, Inc. (REPL) | 2026-03-31 | $221.18M | +16.8% |
Compare KYTX, ALEC, XFOR, LENZ side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗